Lifitegrast 5% Ophthalmic Solution
Sponsors
Weill Medical College of Cornell University, AbbVie, Bucci Laser Vision Institute, Eye Surgeons of Indiana, Research Insight LLC
Conditions
Dry EyeDry Eye DiseaseDry Eye SyndromeDry Eye SyndromesDry Eyes ChronicGraft-versus-host-diseaseOcular Graft-versus-host Disease
Early Phase 1
Phase 1
Phase 2
Phase 4
Effect of Lifitegrast 5% on Tear Film Markers
WithdrawnNCT03952481
Start: 2021-03-01End: 2021-12-31Updated: 2021-02-16
Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra
WithdrawnNCT04120987
Start: 2021-05-31End: 2022-06-25Updated: 2023-07-27
Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease
TerminatedNCT04413253
Start: 2020-08-01End: 2022-04-11Updated: 2022-04-18
The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study
CompletedNCT04669561
Start: 2021-03-17End: 2021-10-08Updated: 2021-10-12
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
CompletedNCT05505292
Start: 2022-09-22End: 2023-05-15Updated: 2025-01-14